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There is significant overlap between the neuropathology of mild traumatic brain 
injury (mTBI) and the cellular role of creatine, as well as evidence of neural creatine 
alterations after mTBI. Creatine supplementation has not been researched in mTBI, 
but shows some potential as a neuroprotective when administered prior to or after 
TBI. Consistent with creatine’s cellular role, supplementation reduced neuronal 
damage, protected against the effects of cellular energy crisis and improved cognitive 
and somatic symptoms. A variety of factors influencing the efficacy of creatine 
supplementation are highlighted, as well as avenues for future research into the 
potential of supplementation as an intervention for mTBI. In particular, the slow 
neural uptake of creatine may mean that greater effects are achieved by pre-emptive 
supplementation in at-risk groups.
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Creatine supplementation has been predom-
inately used for peripheral enhancement, 
increasing muscle function and strength in 
an athletic environment [1] and in those with 
impaired movement [2,3]. However, this mol-
ecule has also begun to be investigated for its 
use in cognitive enhancement in nonclinical 
groups [4], and as a potential neuroprotective 
supplement to reduce damage and alleviate 
symptoms in those with neurological disor-
ders [2,3,5] and brain injury [6,7]. The interest 
in both muscular and neural supplementa-
tion comes from its predominant role in 
energy homeostasis in high or fluctuating 
energy demand tissues such as muscles and 
brain [8]. Increasing the creatine stores in 
the brain could therefore aid in neurodevel-
opmental, psychiatric and acquired injury-
based disorders where there is evidence of 
dysfunctional energy processing or altered 
creatine.
This review investigates the potential for 
creatine supplementation following mild trau-
matic brain injury (mTBI), as well as potential 
neuroprotective effects if taken prior to injury. 
First, the case for a role of creatine in mTBI will 
be discussed, looking at overlap in biology and 
symptom report as well as alterations in neural 
creatine after mTBI. Studies investigating the 
effects of creatine supplementation after trau-
matic brain injury (TBI) will then be summa-
rized, along with its effect in nonclinical and 
related clinical groups. Finally, the factors to 
consider for creatine supplementation, such 
as neural uptake, timing, dosing, i ndividual 
effects and safety issues, will be presented.
The case for a role of creatine in 
mTBI
Overlap in biology
TBI induces both focal damage, where the 
brain impacts the skull, and more diffuse dis-
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ruption in neural function. Focal injury is associated 
with vascular damage in cortical gray matter areas, 
which can lead to secondary damage around the site 
of impact due to ischemia, glutamate neurotoxicity, 
breakdown of the blood–brain barrier (BBB), edema 
and neuroinflammation [9,10]. The role of neuroinflam-
mation after TBI may be beneficial as well as damag-
ing, depending on the time period and circumstances, 
and is still an active area of research [11]. Large-scale 
focal injury is uncommon after mTBI, but there is 
evidence for vascular changes (reduced cerebral blood 
flow and capillary number) and similarities in the met-
abolic cascade that leads to secondary damage such as 
edema and neuroinflammation [12,13].
The primary mechanism for damage in mTBI is 
thought to be the diffuse stretching of axons by inter-
nal shear and strain forces (traumatic axonal injury 
[TAI]) [9,10]. These forces are unlikely to cause immediate 
axonal disconnection or swelling [14], and instead induce 
secondary damage via a metabolic cascade [15–18] of neu-
rochemical, metabolic and inflammatory changes [19–21]. 
This cascade may ultimately result in delayed axonal dis-
connection and swelling or even cell death, but it is more 
probable that axons will remain intact but functionally 
impaired, with altered conduction velocities [14].
In brief, the metabolic cascade [15–18] starts when the 
diffuse stretching of axons makes membranes more 
permeable and allows an ionic flux, whereby there is 
an increase in intracellular calcium and sodium as well 
as extracellular potassium. This leads to nonspecific 
membrane depolarization, which in turn triggers volt-
age or ligand-gated ion channels and an indiscriminate 
release of excitatory neurotransmitters such as glutamate. 
These neurotransmitters bind to synaptic receptors to 
instigate further depolarization and cause a feedback 
loop resulting in a ‘spreading-depression’-like state (see 
Figure 1A) [18]. Depolarized neurons use ATP-dependent 
ionic pumps to try and regain resting membrane poten-
tial, with replenishment of neuronal ATP stores requiring 
increased oxidative respiration and glycolysis. However, 
cerebral oxidative respiration is compromised by vascular 
changes during mTBI (reduced blood flow and impaired 
autoregulation) [13], and impaired mitochondrial func-
tion (due to increased intracellular calcium) [18]. Anaero-
bic glycolysis is increased, resulting in raised intracellular 
lactic acid, but may not be sufficient to provide the extra 
energy required. This process therefore results in a gener-
alized cellular energy crisis (see Figure 1B) [18], with meta-
bolic dysfunction potentially lasting for days or weeks 
after injury [18,20].
Part of the reason for more long-term metabolic alter-
ations could be due to the secondary effects of impaired 
mitochondrial function and increased intracellular cal-
cium. Mitochondria sequester some of the intracellular 
calcium, but this impairs their ability to perform oxida-
tive respiration efficiently and results in the production 
of damaging free radicals and reactive oxygen species 
(ROS) [14,18,21]. These induce oxidative stress, causing 
lipid peroxidation, cytoskeleton damage and perhaps 
even inflammatory changes [13,14,18,22]. Furthermore, 
the altered metabolic environment within mitochon-
dria (increased calcium, oxidative stress, reduced ATP) 
can lead to the formation of mitochondrial permeabil-
ity transition pores (mPTP), which can in turn release 
proteins that induce cell death (apoptosis) [23]. Increased 
intracellular calcium not only impairs mitochondrial 
function, but also activates enzymes that degrade ion 
channels to make them more porous (increasing ionic 
flux), breakdown axonal structures such as the cytoskel-
eton and microtubules (impairing axonal transport), and 
potentially lead to axonal disconnection and even apop-
tosis (see Figure 1C) [12,18]. Finally, alterations in neuro-
transmission have been reported after injury [13,18,19], 
particularly in the cholinergic and catecholaminergic 
(dopamine/adrenergic) systems. There is also evidence 
of altered GABA neurotransmission after injury, with 
reduction perhaps altering the inhibitory-excitatory 
n eurotransmission balance after injury [18].
Creatine (methylguanidoacetic acid) is a naturally 
occurring nitrogenous organic acid, stored predomi-
nately in skeletal muscles [24,25] but also present in the 
liver, kidney, testes and brain [22]. The predominant 
role of creatine (Cr) is to maintain energy homeostasis 
by keeping cellular ATP levels constant in cells with 
high and fluctuating energy demands, such as those 
found in muscles and the brain [4,8,26]. It is in this 
role that the overlap with mTBI neuropathology is 
most apparent, as the cellular energy crisis induced by 
mTBI places an extremely large demand on ATP in an 
e nvironment of reduced blood flow and hypoxia.
Creatine kinase (CK) enzymes within the mitochon-
dria (uMt-CK) transfer the energy stored in ATP to Cr 
by transferring the phosphate group to create Phospho-
creatine (PCr) and ADP (see Figure 1B). In times of low 
energy demand, mitochondria use oxidative respiration 
to create ATP, with some of this energy locked away or 
‘stored’ as PCr. In times of high energy demand, a CK 
in the cytosol (BB-CK) can regenerate ATP from these 
PCr stores as required. As PCr is smaller and less nega-
tively charged than ATP, it is able to move more freely 
through the cell [26], diffusing quickly between the site 
of ATP production (mitochondria) and use (e.g., syn-
apse) [5], where it is able to be stored in large amounts 
for future use [26]. This Cr/PCr/CK mechanism means 
that levels of ATP can remain constant even when the 
energy demand increases by several orders of magni-
tude (‘the stability paradox’ [27]), by both regenerating 
at site of use from local PCr stores (‘temporal energy 
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buffer’), and quickly shuttling newly created PCr from 
mitochondria to the site of use (‘spatial energy buf-
fer’) [2,5,28]. Indeed, it is so efficient in this role that 
ATP levels remain stable until quite severe levels of 
oxygen depletion [26].
Critically for the case of mTBI, the creatine system 
enables cells to regenerate ATP quickly, efficiently 
and without the need for oxygen. All of these prop-
erties would help reduce the generalized energy crisis 
seen after mTBI, where ATP is in high demand for 
restoration of membrane potentials and ion gradients 
(e.g., calcium), neurotransmitter release and reuptake, 
and intracellular transport [22,23,27]. In addition, the 
tight coupling of the creatine system and ATP produc-
tion in mitochondria has other benefits effects on the 
energy status of the cell, which are relevant to mTBI 
neuropathology. As the phosphate from ATP is trans-
ferred to PCr, this increases ADP levels in the mito-
chondria, which stimulates respiration and reduces the 
energy required for ATP synthesis [2,4,26]. Increased use 
of PCr to generate ATP, and increased mitochondrial 
efficiency reduces the amount of glycolysis required, 
and thus the amount of lactic acid accumulation [3,4].
In addition to beneficial effects on cell energy status, 
creatine has a role in the secondary mechanisms related 
to mitochondrial dysfunction and increased calcium 
homeostasis observed after mTBI. The tight coupling 
of creatine and ATP in mitochondria may also reduce 
the likelihood of the formation of ROS, thereby hav-
ing an antioxidant effect [4,7,28,29]. It is also thought 
that creatine may have a more direct antioxidant role 
as a scavenger of free radicals and reactive species [2,7]. 
Regeneration of ATP and reduction of free inorganic 
phosphate by BB-CK aids in calcium homeostasis [2] 
(Figure 1C), decreasing both intracellular and mito-
chondrial calcium. Furthermore, creatine reduces the 
Figure 1. The neurometabolic cascade after mTBI, and its overlap with creatine biology (in red). (A) How diffuse 
injury after mTBI results in large-scale membrane depolarisation (a ‘spreading depression’-like state), reduced 
blood flow and increased intracellular calcium. (B) The generalised cellular energy crisis, where large amounts of 
ATP are required to repolarise the membranes and counteract the ‘spreading depression’-like state. This occurs in 
a low oxygen environment, with dysfunctional mitochondria (due to calcium sequestering), resulting in increased 
glycolysis and lactic acid formation, along with increased oxidative stress and potential formation of mPTP. (C) The 
secondary effects of increased intracellular calcium. Red boxes and arrows indicate the role and influence of 
creatine within mTBI neuropathology. 
ADP: Adenosine di-phosphate; ATP: Adenosine tri-phosphate; BB-CK: Braincreatine kinase; Cr: Creatine; 
mPTP: Mitochondrial permeability transition pore; mTBI: Mild traumatic brain injury; PCr: Phosphocreatine; 
ROS: Reactive oxygen species; uMt-CK: Ubiquitous mitochondrial creatine kinase.
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likelihood of mPTP developing in the mitochondria by 
protecting against the factors involved in their forma-
tion. The Cr/PCr/CK system may also help stabilize 
the mPTP, preventing it from opening and releasing 
proteins into the cytosol to induce apoptosis [3,23,29], 
although this effect may be weak or indirect [7,30]. Cre-
atine may therefore play a role in the moderation of 
oxidative stress, intracellular calcium and apoptotic 
effects in neurons after mTBI.
Finally, there is tentative evidence that creatine could 
potentially influence edema, inflammation and altered 
neurotransmission after mTBI (Figure 1A). Creatine is 
an osmolyte, with supplementation leading to increased 
water retention [23,26,29]. In this way, creatine retention or 
release can alter water retention and osmolarity of cells 
exposed to hyper- and hypo-osmotic stress (e.g., in edema 
or calcium influx) [3,23]. Creatine has also been ascribed 
a putative anti-inflammatory role, reducing the appear-
ance of inflammation markers and perhaps dampening 
immune response [3,29,31]. However, the exact mechanism 
of this effect is unknown, and may be secondary to its 
effects on energy metabolism and scavenging of free radi-
cals (see Figure 1). Lastly, there is evidence that creatine 
may act like a neurotransmitter, with an agonist effect on 
GABA receptors, and some evidence of an influence on 
N-methyl-d-aspartate receptors [4,5,23,26].
In summary, there is considerable overlap between 
the role of creatine and the neuropathology of mTBI 
(Figure 1 & Table 1). Creatine’s role in energy homeo-
stasis, keeping ATP levels constant and increasing 
the efficiency of mitochondrial oxidative respiration 
has particular potential value during the generalized 
energy crisis observed after mTBI. In addition, creatine 
has a role in calcium homeostasis, reducing oxidative 
stress and potentially aiding in edema, neuroinflam-
mation and altered neurotransmission.
Evidence for altered creatine after mTBI
In general, the most consistent finding in the acute stage 
after mTBI is reduced N-acetyl aspartate (NAA; suggest-
Table 1. Overlap between mild traumatic brain injury neuropathology, role of creatine and symptom report.
mTBI neuropathology† Creatine role‡ PCS symptoms† 
Membrane depolarization 
– Ionic flux 
– Spreading depression
– Maintains/restores membrane 
potentials [27] 
– ‘ATP buffer’ [2]
Migraine-like symptoms 
(headache, dizziness, light and sound 
sensitivity)
Calcium influx 
– Impair mitochondria 
– Activate proteases 
– Possible apoptosis 
– Axonal transport and structure 
effected (cytoskeleton/microtubules)
– Plays a role in calcium homeostasis [2] 
– Prevents influx of calcium 
– ATP buffer (cell transport) [2]
PCS symptoms, specifically cognition 
(related to axonal dysfunction/cell 
death)
Impaired mitochondrial function – Plays a role in calcium homeostasis [2] 
– Prevents influx of calcium 
– Stimulates respiration [2,26] 
– Prevents formation of mPTP and stabilizes 
mPTP, preventing pore opening [3]
Increased vulnerability (Second Impact 
Syndrome)
Oxidative stress 
– Production of ROS & free radicals
– Reduces ROS by aiding mitochondria [4] 
– Directly scavenges free radicals [2]
Increased vulnerability (Second Impact 
Syndrome)
Glutamate excitotoxicity – Aids neurotransmission and reuptake [27] 
– Protects against glutamate toxicity
 
Lactate accumulation Buffers lactate accumulation by reducing 
glycolysis [3,4]
 
Swelling/edema Used as osmolyte in brain [26]  
Inflammation – Putative anti-inflammatory role [3,31] 
– Role in reducing glutamate excitotoxicity
 
Altered neurotransmission balance 
– Reduced GABA 
– Altered inhib–exit balance
Putative role as neurotransmitter for GABA 
and NMDA receptors [4,26]
PCS symptoms, specifically cognition 
(related to axonal dysfunction/cell 
death)
†Data taken from [16,18]. 
‡Data taken from [26,27]. 
inhib–excit: Inhibitory-excitatory; mPTP: Mitochondrial permeability transition pores; mTBI: Mild traumatic brain injury; NMDA: N-methyl- d -aspartate; PCS: Post-
concussion syndrome; ROS: Reactive oxygen species.
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ing neuronal loss [32–34]), with some evidence of increased 
choline (suggesting cell turnover or loss [8]), lactate (gly-
colysis [35]) and myoinositol (suggesting inflammation 
and osmotic stress [36]). Furthermore, NAA is reduced 
more in those with greater postconcussion syndrome 
(PCS) [33], and correlates with cognitive performance [34].
However, findings for total creatine are more variable, 
with both increases [8,37] and decreases [38,39] observed 
after mTBI. This variability may be due to the areas 
investigated in these studies, as creatine concentration 
is highest in gray matter areas (cerebral cortex, hippo-
campus, olfactory bulb, brainstem, cerebellum, spinal 
cord) and lowest in white matter areas and basal gan-
glia [5,26]. Furthermore, there is differential expression 
of the creatine transporter (CRT; required for creatine 
uptake) along similar lines [40]. If split by tissue type, 
the creatine results become more understandable, with 
increased creatine observed in white matter areas [8], 
and no difference or reduced creatine in gray matter or 
mixed areas [38,39]. Therefore, in areas with high creatine 
concentration (gray matter), the general finding is either 
unaltered or reduced creatine [38,39]. The degree of altera-
tion may depend on the severity of injury, or the propor-
tion of gray and white matter in mixed areas. Further-
more, the reduced gray matter creatine (usually high) 
and increased white matter creatine (usually low) could 
indicate some breakdown in the spatial energy buffer 
function. Overall, these findings suggest that mTBI 
can directly affect neural creatine stores, and there is 
evidence of a correlation between creatine and cognitive 
performance [41], as well as time since injury [42].
There is also recent evidence for reduced creatine 
concentration in gray matter areas (primary motor 
area and dorsolateral prefrontal cortex) over the course 
of an American football season, even when no mTBI 
was recorded [43]. This reduction in total creatine was 
related to the number of high force (60+G) subcon-
cussive impacts recorded [44]. These studies demon-
strate a relationship between head impact and creatine 
concentration at a subconcussive level, and suggest a 
mechanism for the increased vulnerability to injury 
(Second Impact Syndrome, discussed in the next 
section [15,18,21]). In addition, the use of longitudinal 
data, with baseline (preseason) concentration measure-
ments, allow firmer conclusions to be drawn about the 
relationship between head impact and creatine.
The relative paucity of studies into creatine differences 
after mTBI could be due to the fact it was thought to 
be stable within both clinical and nonclinical popula-
tions, and so is typically used as an additional reference 
within magnetic resonance spectroscopy (MRS) analy-
ses (e.g., NAA/Cr). However, creatine concentration is 
not constant [26], as it depends on tissue type, amount 
of activity, degree of vasculature, and varies across clini-
cal groups [26]. There is clearly a need for more research, 
as current findings indicate that mTBI may affect neu-
ral creatine concentration, and that the concentration 
postinjury is related to cognitive performance.
Overlap in symptoms
After an mTBI, individuals commonly report a number 
of somatic, cognitive and emotional symptoms, collec-
tively known as PCS. There is evidence that these symp-
toms may result from aspects of the neurometabolic 
cascade observed after mTBI. For instance, the initial 
ionic flux could underlie very acute PCS symptoms. It 
induces a ‘spreading depression’ very similar to that seen 
in migraine, with similar symptoms reported (headache, 
nausea, light sensitivity, sound sensitivity and dizzi-
ness) [18]. Some PCS symptoms may also be explained 
by axonal dysfunction and altered neurotransmission 
after mTBI. Indeed, this relationship has been observed 
in diffusion tensor imaging ([45–50]) and functional MRI 
([51–55]) studies, with altered structure (axonal integrity) 
and function related to slowed cognition and reaction 
time. In addition, the cellular energy crisis seen after 
mTBI may last for a considerable time after injury, and 
may even be present after subconcussive injury [43,44]. 
This energy crisis not only impacts on somatic and cog-
nitive function as mentioned above but also increases 
vulnerability to a second injury with potentially longer-
lasting and more severe deficits (Second Impact Syn-
drome [15,18,21]). This ‘window’ of vulnerability could 
also mean that compensation mechanisms develop on 
a behavioral or physiological level, with perhaps greater 
effort or altered neural functioning underlying some 
PCS symptoms such as fatigue and headache [56].
It is clear that creatine’s role in energy homeostasis is 
directly associated with the cellular energy crisis, ionic 
flux, axonal disconnection and altered neurotransmis-
sion, which may underlie PCS symptom report after 
mTBI (see Table 1 for summary of biological overlap 
with symptom report). However, further evidence for 
the potential role of creatine in PCS symptom report 
comes from individuals with impairments in creatine 
metabolism. For instance, impairment in the Cr/PCr/
CK system can cause predisposition to migraines [57], 
perhaps via a reduced ability to control for ionic flux, 
developing into ‘spreading depression’, similar to the 
state observed after mTBI. Individuals with extremely 
low neural creatine concentration, due to genetic 
alterations in creatine synthesis or transport, exhibit 
symptoms such as mental retardation, language delay, 
developmental delay, motor disorders and neurological 
symptoms (e.g., seizures) [4,23,58]. These are much more 
severe symptoms than those observed in PCS, but dem-
onstrate the necessity of creatine for typical cognitive 
and motor function. Large alterations in creatine cause 
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drastic symptoms, but this also suggests that less severe 
symptoms may be caused by the relatively small altera-
tions observed after mTBI. Furthermore, and of clear 
relevance to this review, early use of creatine supplemen-
tation in individuals with creatine synthesis deficien-
cies can alleviate these symptoms, and may reduce the 
majority of these effects on the brain [4,23,58].
Creatine supplementation
Creatine supplementation is predominately used to 
enhance muscle function in athletes [1], the military [59] 
and in clinical movement disorders [2,3]. However, there is 
also research into whether supplementation may enhance 
cognition in general nonclinical [4] and ageing popula-
tions [25], as well as the possibility of using it as a neu-
roprotective in neurodegenerative diseases (e.g., Parkin-
son’s disease, Huntingdon’s disease, Alzheimer’s disease, 
amyotrophic lateral sclerosis, Charcot-Marie-Tooth’s 
disease, fibromyalgia) [2,3,22,60,61], psychiatric disorders 
(e.g., schizophrenia, bipolar disorder, major depression, 
anxiety disorders and psychological stress) [5,62] and 
brain injury (both TBI [2–4,6] and stroke [3,4,7,22]). The 
extensive list of applications gives an idea of the scope of 
research into the neural effects of creatine supplementa-
tion. However, underneath each of these applications is 
the effect of creatine on cerebral energy depletion, oxida-
tive stress and mitochondrial dysfunction [2] or evidence 
of altered creatine metabolism within the clinical state 
(e.g., psychiatric diseases [5]).
Creatine supplementation in (m)TBI
Several reviews have suggested the applicability of cre-
atine supplementation to TBI [3,6], and there is a strong 
case for the potential of creatine in mTBI (see previ-
ous section). Despite this, there are no known studies 
into the effect of such supplementation on mTBI, and 
very few studies examining its effect on TBI. However, 
those studies that exist show promising results, and 
will be discussed in this section.
In animal models, creatine supplementation prior to 
experimental TBI reduced cortical damage (36–50% 
reduction) by protecting mitochondrial function (mito-
chondrial membrane potential increased, lower intra-
mitochondrial ROS and calcium, ATP levels main-
tained) [63] and protected against some of the effects 
of oxidative stress (but not seizure susceptibility) [64]. 
Higher levels of supplementation produced a greater 
degree of neuroprotection, as indicated by lower mark-
ers of secondary injury (lactate and free fatty acids) [65]. 
However, an in vitro study of rat hippocampal cells sug-
gested that creatine supplementation may not have a 
direct protective effect for oxidative stress, with protec-
tive effects perhaps based on reduced glutamate and cal-
cium excitotoxicity and increased ATP/PCr levels [66].
In clinical populations, the only studies known to 
date come from Sakellaris and colleagues [67–69]. These 
studies investigated the effects of creatine supple-
mentation (0.4 g/kg in oral suspension for 6 months) 
after TBI (Glasgow Coma Scale: 3–9; within 4 h of 
time of injury) in children and adolescents (age: 1–18 
years old) [67–69]. Administration of creatine reduced 
post-traumatic amnesia and improved recovery [67–
69], cognitive function [67], headaches, dizziness and 
fatigue [68], as well as language articulation and under-
standing [69]. It should be noted that these studies were 
conducted in children, after severe to moderate TBI, in 
open-label trials.
Overall, these studies demonstrate that creatine 
supplementation after TBI causes alterations in bio-
logical markers related to mTBI neuropathology (in 
animal models), as well as improved outcome and 
reduced symptom report (in clinical studies) in areas 
expected from the overlap between mTBI, creatine and 
symptom report (see Figure 1 & Table 1). Further inves-
tigation is therefore warranted for the potential use in 
mTBI populations, using double-blind interventions.
Creatine supplementation in other nonclinical 
& clinical groups
There are further indications of the utility of creatine 
supplementation for mTBI in its effects on nonclinical 
and clinical populations. In nonclinical populations, 
creatine supplementation has been shown to increase 
cognitive performance, in particular working memory 
and speed of processing, in both young and old partici-
pants [4,5,25]. Along with subjective report of attention 
and memory problems, objective working memory and 
speed of processing deficits are also commonly observed 
after mTBI [70]. Creatine supplementation has also 
been shown to reduce blood–oxygen level-dependent 
(BOLD) response in a functional MRI visual process-
ing task [71]. This reduction in BOLD response may be 
due to increased PCr stores reducing the immediate need 
for increased oxygen and glucose from the blood. It also 
demonstrates the potential for creatine to ameliorate the 
altered BOLD response during cognitive tasks observed 
after mTBI [56]. Of particular interest to mTBI research, 
the effect on cognition is greatest when creatine is supple-
mented prior to an intervention that compromises cell 
energy status, such as experimental hypoxia [4,5,72]. In 
addition, creatine supplementation prior to experimental 
ischemia in animal models and in vitro studies resulted in 
reduced damage, lower lactate and higher ATP in supple-
mented animals [7]. This is a similar state to the cellular 
energy crisis after mTBI, and demonstrates strong poten-
tial for neuroprotective effects of creatine administered 
prior to injury. Finally, there is some evidence that cre-
atine may improve outcome in mood disorders such as 
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depression [5] and post-traumatic stress disorder [4], both 
of which are common co-morbid diagnoses after mTBI.
Creatine supplementation summary
The literature on creatine supplementation after TBI 
is sparse, but those studies that do exist suggest a 
potentially useful role for this compound in alleviat-
ing secondary damage after injury as well as protecting 
against damage if administered pre-injury. The possi-
ble protective role is particularly interesting when con-
sidering that two populations with high risk of mTBI 
are already taking this compound to some degree 
– athletes [1] and the military [59]. This fact would 
enable longitudinal studies into ability of creatine 
supplementation to protect against the effects of mTBI 
and subconcussive injury over a season or deployment.
However, it is clear from the literature on creatine 
supplementation that promising findings in animal 
models or in vitro have not always been followed by 
conclusive findings in human participants [4], particu-
larly in clinical populations [60]. Therefore, the use of 
creatine as a neural supplement still requires research, 
as there are many unanswered questions and many 
f actors influencing its potential utility.
Factors to consider for creatine 
supplementation
The most pressing factor influencing the efficacy of 
creatine supplementation is its pharmacokinetics [73]. 
Specifically, how much does supplementation actually 
increase creatine levels in the brain? Dietary creatine 
reaches the neurons by crossing from the gut into the 
bloodstream, and must then be transported across the 
BBB. The increase in neural creatine after supplemen-
tation would depend on the mechanisms for creatine 
transport (and synthesis) in the brain, the timing of 
administration, dosing regimen, the type and form of 
creatine administration, and individual factors such as 
age and gender. In addition, researchers must be aware 
of the safety considerations for supplementation.
Creatine synthesis & transport in the brain
The majority of individuals get around half of the typi-
cal daily requirement for creatine (∼2 g/day [23,26]) from 
a diet that contains meat and dairy products [3,5,23,24,29], 
with the other half being synthesized within the 
body [3,5,57]. This synthesis is a two-step process occur-
ring predominately in the kidneys and liver [5,24], but 
also in the brain [5,23,26]. In brief, in the first step the 
enzyme AGAT converts arginine and glycine into gua-
nidinoacetatic acid, and in the second step the enzyme 
GAMT converts this guanidinoacetatic acid and S-ade-
nosylmethionine into creatine [5,24]. Both dietary and 
endogenously synthesized creatine is taken up into cells 
using a CRT [5,24]. The final stage in the cycle of creatine 
is its breakdown into creatinine, which is then removed 
in the urine (∼1.5–2% or 2 g/day) [3,24].
CRTs at the BBB are essential for supplementary cre-
atine to enter the brain. However, although CRT are 
present within neurons, oligodendrocytes and on the 
microcapillary endothelial cells that line the BBB, they 
do not seem to be present in the astrocytic feet which 
cover around 98% of the BBB [5,24,74]. This leaves only 
a small amount of surface available for creatine absorp-
tion, and may therefore mean that effects of supplemen-
tation are at most small and slow-acting. Indeed, creatine 
supplementation does not significantly change neural 
creatine concentrations, or aid symptoms, in individuals 
with CRT deficiencies [4,23,58], highlighting its key role 
in neural uptake. In contrast, individuals with intact 
CRT, but deficient in creatine synthesis, show marked 
improvements in neural creatine concentrations, as well 
as symptom alleviation and reduced neural damage 
after long-term supplementation [4,23,58]. This demon-
strates that despite their relatively low expression at the 
BBB, CRTs are capable of absorbing creatine from the 
plasma in sufficient q uantities over time.
Creatine synthesis is tightly regulated to keep neu-
ral levels stable, so increased uptake of dietary cre-
atine may result in reduced endogenous synthesis as a 
homeostatic mechanism [24]. Evidence for the poten-
tial power of this homeostatic mechanism comes from 
studies looking at neural creatine concentration in 
vegetarians and vegans, who may receive little or no 
dietary creatine [24]. If dietary intake is essential, then 
vegetarians and vegans should have lower muscular and 
neural creatine. However, it seems that although mus-
cle creatine levels are lower in vegetarians [24], neural 
levels are similar to omnivores [75]. It therefore appears 
that endogenous creatine synthesis may be able to com-
pensate for reduced dietary intake, using homeostatic 
mechanisms to keep neural concentrations similar to 
those in omnivores.
Neural increase of creatine after 
supplementation
As creatine supplementation may produce only small and 
slow acting effects on neural creatine concentrations, it 
is imperative for future studies to monitor both the neu-
ral creatine concentration (using MRS) and the clinical 
effects of supplementation (e.g., cognition) [5,25]. Current 
studies have predominately examined these factors in iso-
lation, precluding direct investigation of the relationship 
between creatine concentration and clinical outcome [25]. 
This is particularly important because creatine supple-
mentation may have a greater peripheral (e.g., muscu-
lar) effect in comparison to its putative role in cognitive 
enhancement and neuroprotection.
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Indeed, creatine supplementation has been shown to 
increase creatine concentration in plasma [76] and mus-
cles [61]. Despite the potentially poor BBB permeabil-
ity, a few studies have also demonstrated that creatine 
supplementation can result in significant increases in 
neural creatine and PCr [72,77–79] (see Table 2). Only one 
of these studies looked at outcome measures, and found 
that creatine supplementation increases neural cre-
atine in primary motor cortex and protected against a 
hypoxia-induced reduction in attention [72]. This study 
allows direct comparison of neural creatine alteration 
and behavioral performance and elegantly de monstrates 
the potential for creatine supplementation.
It seems that identification of statistically significant 
changes in creatine may depend on the neural area stud-
ied. The concentration of creatine varies across neural 
areas [25,26], and greater magnitude increases may be 
observed in those areas with lower presupplementation 
concentrations [5,25]. Indeed, one study did demonstrate 
greater increase in white matter (11.5%, initially low 
creatine area) compared with gray matter and cerebel-
lum (4.7 and 5.4%, initially high creatine areas) after 
supplementation (see Table 2) [77]. Therefore, the choice 
of neural area(s) to sample after creatine supplementa-
tion is an important methodological issue. The choice 
of analysis tool also seems to be potentially important, 
with one study suggesting that the jMRUI software uses 
a technique that is more sensitive to subtle changes in 
creatine compared with LCModel [80]. Measurement of 
creatine concentration changes after supplementation is 
therefore methodologically possible, but potentially chal-
lenging in terms of correct choice of acquisition param-
eters and analysis tools. In particular, methods develop-
ment is required to enable reliable identification of more 
subtle concentration changes and to reduce v ariability in 
p lacement of MRS voxel across acquisitions.
Timing of supplementation
As discussed previously, the results from clinical trials 
have been variable despite very promising findings from 
animal and in vitro models. This could be due to the tim-
ing of creatine supplementation. In animal models, cre-
atine can be given prior to injury, resulting in an imme-
diate neuroprotective effect. However, in clinical studies, 
creatine supplementation can only be started after the 
clinical condition has been diagnosed. This will at best 
be in the subacute stage (within hours) after injury, when 
damage will already have occurred. Furthermore, as the 
putative neural increase in creatine is slow, further sec-
ondary damage might occur before an effective concen-
tration is reached. Post-injury creatine supplementation 
may therefore be too late to enable some of the protective 
effects of creatine [60], resulting in reduced efficacy in 
comparison to the animal models.
The timing of supplementation is therefore likely 
to be critical for the scale and nature of the effect it 
exerts. Animal models with pre-TBI supplementation 
show larger neuroprotective effects such as reduced 
cortical damage, oxidative stress (ROS) and improved 
mitochondrial function [63–66], whereas clinical studies 
with post-TBI supplementation demonstrate improved 
symptom report such as cognitive function, headaches 
and fatigue [67–69]. We would therefore predict that cre-
atine supplementation will have much greater efficacy 
in reducing neural damage and moderating PCS symp-
toms if used as a pre-emptive neuroprotective in high-
risk populations (e.g., athletes and military [1,59]), rather 
than a postinjury medication. These high-risk popu-
lations for mTBI are already taking creatine to some 
degree in order to improve muscle strength and stam-
ina [1,59], meaning the potential neuroprotective effects 
of this compound could be relatively easily studied.
Strength, length & dosing regime in creatine 
supplementation
Previous studies use a variety of dosing regimens for 
creatine supplementation, and no definitive guidelines 
have been set [5]. In general, traditional supplemen-
tation protocols include a short (3–7 days) ‘loading 
phase’ with high-dose creatine (15–20 g/day) and/or 
a longer duration ‘maintenance phase’ of 1–3 months 
(3–10 g/day) [2,3,5] (e.g., see Table 2). As neural uptake 
of creatine is slow, it seems that prolonged administra-
tion (several days) and/or high dose is required [2,5,7], 
with studies using short supplementation or doses 
lower than 5 g reporting no significant changes in 
neural creatine [4,83]. It has also been suggested that 
the difference in outcome between animal models and 
clinical trials in humans [2] may be due to the size of 
the dose given (several times higher in animals) [60]. 
However, doses of up to 40 g/day have been trailed in 
individuals with Huntington’s disease with little clini-
cal effect [60], and (biological) effects are observed in 
animal models with doses comparable to human trials 
(0.3 g/kg or 21 g for 70 kg) [64].
Furthermore, there may be a U-shaped dose–response 
curve, where lower doses are not enough to increase 
neural creatine, but higher doses may actually slow the 
absorption of creatine [5,60]. More specifically, higher 
doses may saturate CRTs in the intestines causing their 
downregulation [5], with the majority of the dose being 
simply excreted [5], and may be more likely to trigger 
other homeostatic mechanisms such as reduction in 
endogenous creatine synthesis [24]. High doses of cre-
atine may also have issues for safety in short- or long-
term supplementation (see the ‘Safety of creatine supple-
mentation’ section). For this reason, studies usually split 
creatine supplementation into smaller doses across the 
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day, with some variability in the number and strength 
of doses (Table 2). In general, multiple small doses 
(e.g., 5–10 g across the day, see Table 2) are preferred, 
with long-term doses greater than 10 g potentially hav-
ing a counter-productive effect [5].
Finally, the form of administration and type of com-
pound also influence uptake of creatine. Orally admin-
istered creatine must be able to survive the highly acidic 
stomach environment (which may break it down to cre-
atinine [3]) to be transported from the intestines (where 
bacteria may also break it down) into the bloodstream. 
The form of administration (solution, powder or cap-
sule) influences its ability to negotiate these environ-
ments as well as the speed it is absorbed into the plasma. 
Creatine in solution reaches peak plasma concentration 
first, and all supplemental creatine peaks quicker than 
dietary creatine [5]. One final obstacle for creatine to 
negotiate after supplementation is the BBB, where the 
limited amount of CRT means neural uptake is small 
and slow-acting. A number of compounds have been 
trialled for their increased ability to penetrate the BBB, 
with cyclocreatine and PCr–Mg complex acetate both 
able to enter the brain even when the CRT is inactive [7]. 
Creatine ethyl ester also has increased cell permeability, 
and is stable at lower pH, increasing its stability in the 
stomach environment [3]. These are potentially useful 
compounds for future research. However, the majority 
of studies use creatine monohydrate in solution as part of 
their supplementation protocol (see Table 2).
Interindividual variability effects on creatine 
supplementation
Individual variation in diet, age and gender has been sug-
gested to influence neural creatine levels, which in turn 
has been suggested to influence the effects of creatine 
supplementation (greater effects observed in areas with 
lower presupplementation creatine concentration) [5,25]. 
As discussed previously, the differences in dietary uptake 
of creatine between vegetarians and omnivores exhibit 
no influence on neural creatine concentration [75].
Current research reports both decreased [25] and 
increased [5] neural creatine with increasing age. This 
discrepancy could be due to marginal changes over 
age or due to variation in neural area investigated. The 
effect of healthy ageing on neural creatine has not been 
sufficiently researched, and longitudinal data are lack-
ing [25]. This is of particular interest as cerebral energy 
depletion plays a major part in brain injury and is 
thought to be an underlying factor in some age-related 
neurodegenerative diseases [2].
There is also limited evidence for gender-related differ-
ences in creatine concentration, with one study reporting 
lower frontal lobe PCr concentration in healthy women 
compared with healthy men [5]. In addition, creatine 
supplementation showed some benefit in female, but not 
male, rats in a model of depression [5]. This does suggest 
some interaction between gender and creatine efficacy, 
at least in depression, and may be due to the influence 
of gender-related hormones and hormone cycles [5]. As 
the menstrual cycle also influences PCS symptom report 
after mTBI [84], and given the putative neuroprotective 
role of progesterone [85], this is particularly relevant to the 
d evelopment of e ffective creatine applications in mTBI.
Safety of creatine supplementation
Side effects such as muscle cramping, diarrhea, nausea, 
vomiting, dehydration, water retention, mood altera-
tion and kidney dysfunction have been reported after 
creatine supplementation [2,5,7,60,86]. Muscle cramps 
and gastrointestinal distress (diarrhea, nausea, vomit-
ing) are likely due to altered osmotic balance and dehy-
dration [86]. As such, it is recommended to drink extra 
water during supplementation, make sure that the sup-
plement is fully dissolved before ingestion, avoid single 
high doses (perhaps >10 g) [2,86] and avoid caffeine [5]. 
Creatine supplementation can cause high creatinine in 
the urine (due to increased creatine breakdown), which 
is sometimes used as an indicator of kidney dysfunc-
tion and may therefore lead to false positives in these 
tests [86]. However, to ensure safe supplementation, it is 
recommended to spread the dose out evenly through-
out the day, or use slow-release creatine to reduce any 
possible buildup of toxic compounds.
In general, creatine supplementation in traditional 
doses, using pure compound, is deemed safe [7,86]. How-
ever, use of creatine with other compounds known 
to have an adverse effect of kidney function may be 
unwise [86]. Long-term supplementation at or below 
5 g/day is considered safe, with more data required for 
higher doses, although there is no indication for safety 
concerns [7]. Regular recording of kidney function dur-
ing high-dose creatine supplementation is recommended 
to help early identification of unintended side effects and 
provide empirical data for the safety of such a regime [86]. 
As discussed above (see the ‘Strength, length and dosing 
regime in creatine supplementation’ section), high-dose 
creatine may also have effects in regulation of creatine 
synthesis and uptake, though this should stabilize after 
supplementation is discontinued.
Conclusion & future perspective
Creatine supplementation demonstrates potential as 
a neuroprotective when administered prior to or after 
mTBI. There is significant overlap between the neu-
ropathology of mTBI, the cellular role of creatine and 
PCS symptom report, as well as evidence of neural cre-
atine alterations after mTBI and subconcussive injury. 
Furthermore, supplementation before experimental 
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TBI reduced markers of cellular damage and energy 
crisis, and supplementation after clinical TBI improved 
outcome and reduced symptom severity. However, 
despite this promise, there is no known research l ooking 
s pecifically at supplementation after mTBI.
Creatine is a safe, naturally occurring compound, 
both endogenously synthesized and present in the diet, 
and is widely used as a supplement to build muscle 
strength and stamina. The efficacy of creatine supple-
mentation for neural effects requires greater scrutiny; 
its ability to increase neural creatine concentration 
depends on an effective dose regime as well as differ-
ences in presupplementation creatine concentration. 
The exact mechanism and pharmocokinetics of cre-
atine supplementation for neural effects has yet to be 
fully understood. For this reason, it is essential that 
supplementation studies monitor neural creatine con-
centration as well as behavioral and clinical outcome 
to allow firm conclusions to be drawn.
Looking forward, there is a large gap in the litera-
ture on creatine supplementation, with future studies 
required to investigate its potential following mTBI. In 
particular, creatine supplementation may have much 
greater efficacy if used as a pre-emptive neuroprotec-
tive in populations at high risk of mTBI (athletes and 
military), rather than a postinjury medication. As these 
high-risk populations are already taking supplement to 
some degree for muscle strength and stamina, this may 
enable longitudinal studies investigating neuroprotec-
tion against the effects of mTBI and subconcussive 
injury over a season or deployment. These future studies 
should also bear in mind the dosing regimen and safety 
recommendations detailed in this review.
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Executive summary
The case for a role of creatine in mild traumatic brain injury
•	 There is considerable overlap between the neuropathology of mild traumatic brain injury (mTBI) and the role 
of creatine in the brain.
•	 Neural creatine concentrations are altered after mTBI and subconcussive injury, with a reduction (or no 
change) in gray matter areas and an increase in white matter areas.
•	 The post-concussion syndrome symptoms reported after mTBI share some similarity to those reported in 
individuals with impairments in creatine metabolism, and may both be due to a shared underlying cellular 
energy deficit.
Creatine supplementation
•	 Few studies have looked at creatine supplementation after traumatic brain injury (TBI), with none 
investigating mTBI.
•	 However, these TBI studies demonstrate that creatine supplementation can have both neuroprotective effects 
in animal models (e.g., protect mitochondrial function, antioxidant effects and increased ATP) and in clinical 
cohorts (e.g., improve recovery, reduce headache, dizziness, fatigue, improved cognition).
•	 Creatine supplementation also improves cognition in nonclinical populations, outcome in anxiety and 
depression-related mood disorders, and has a protective effect in situations that impair cell energy status.
Factors to consider for creatine supplementation
•	 The efficacy of creatine supplementation is dependent on its ability to increase neural concentration, this 
increase may be small and slow due to limited creatine transporter at the blood–brain barrier.
•	 Other factors that affect efficacy are dosage regime (amount, doses/day, length of supplementation, type 
of administration, form of compound), prior neural concentration (which varies across areas and may be 
influenced by diet, age and gender) and tolerance (safety of administration, hydration status).
•	 Of particular interest, pre-emptive supplementation prior to injury (as in animal models) may have a greater 
neuroprotective effect than postinjury supplementation.
Conclusion & future perspective
•	 Creatine supplementation demonstrates potential as a neuroprotective both before and after TBI, but there is 
a gap in the literature for research into supplementation following mTBI.
•	 In particular, creatine may have potential as a pre-emptive neuroprotective against mTBI and subconcussive 
injury in high-risk populations such as athletes and military personnel.
www.futuremedicine.com 10.2217/cnc-2016-0016future science group
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